Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lei Ling

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Journal of Hepatology|April 15, 2018
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitisKatharina Brandl, Phillipp Hartmann, Lily J Jih, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Journal of Hepatology|April 15, 2018
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitisKatharina Brandl, Phillipp Hartmann, Lily J Jih, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
Pageof 11